Stock market today: Dow, S&P 500, Nasdaq waver with US-China trade talks, Fed rate decisio
May 7, 2025
LIVE
Updated 34 mins ago
US stocks were mixed on Wednesday as investors assessed prospects for planned US-China trade talks and waited for the Federal Reserve’s latest interest rate decision to land.
The benchmark S&P 500 (^GSPC) was up about 0.2% while the tech-heavy Nasdaq Composite (^IXIC) fell about 0.3%. The Dow Jones Industrial Average (^DJI) rose about 0.6%, or about 250 points. A sharp 5% drop in Alphabet (GOOGL,GOOG) shares weighed on the Nasdaq, while a 10% pop in Disney (DIS) stock powered the Dow higher.
Markets cautiously welcomed news on Tuesday that top US and Chinese officials will meet this weekend for the first major trade talks between the two since President Trump hiked tariffs on Chinese imports to 145% in April.
^GSPC ^DJI ^IXIC
Faith in the idea that the US and China would eventually get around the table to seal an agreement has helped keep stocks aloft in recent weeks. But signs are that the Geneva meeting won’t bring a big trade deal.
“We’ve got to deescalate before we move forward,” Treasury Secretary Scott Bessent said in an interview on Fox News.
Read more: The latest on Trump’s tariffs
Striking the same note, Trump on Tuesday downplayed the idea that countries could negotiate better tariffs. Speaking at a meeting with Canadian Prime Minister Mark Carney, he laid out a “take it or leave it” choice for US trading partners.
Investors are now getting ready for the Fed’s policy decision due at 2 p.m. ET. Traders are pricing in about 96% odds that the central bank will leave rates unchanged, according the CME’s FedWatch tool. The focus will be on what Chair Jerome Powell has to say about the economy and the future path of rates as the impact of Trump’s historic tariff hikes feeds through.
On the earnings front, Disney lifted its profit outlook after delivering an earnings beat driven by a rebound in its US parks business and strong performance in its streaming unit. Novo Nordisk (NVO, NOVO-B.CO) cut its 2025 sales and profit forecasts, but its shares rose on hopes a copycat ban will help sales of its Wegovy weight-loss drug.
LIVE 17 updates
-
-
-
-
-
Yahoo Finance’s Ben Werschkul reports:
-
-
-
-
-
-
-
-
-
-
-
-
Terms and Privacy Policy
Search
RECENT PRESS RELEASES
Related Post